Designer Oncolytic Adenovirus: Coming of Age

The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic virotherapy, since it provided unequivocal evidence for the long-touted potential of genetically modified replicating viruses as anti-cancer agents. Whilst T-Vec is promising as a locally delivered virother...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Alexander T., Aguirre-Hernández, Carmen, Halldén, Gunnel, Parker, Alan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025169/
https://www.ncbi.nlm.nih.gov/pubmed/29904022
http://dx.doi.org/10.3390/cancers10060201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025169/
https://www.ncbi.nlm.nih.gov/pubmed/29904022
http://dx.doi.org/10.3390/cancers10060201

Ejemplares similares